Freer R J, Stewart J M
Arch Int Pharmacodyn Ther. 1975 Sep;217(1):97-109.
Involvement of the pulmonary vasculature of the rat in the in vivo metabolism of bradykinin, angiotensin I and 5-hydroxytryptamine was studied by monitoring the systemic blood pressure response of the test animal during intravenous or intraarterial administration of these substances. Observation of essentially the same blood pressure response regardless of the route of injection indicated that neither agiotensins I or II nor 5-hydroxytryptamine was metabolized by the pulmonary vasculature, while bradykinin was inactivated to the extent of 95+% on one passage through the lung. In the rat the major portion of bradykinin inactivation and angiotensin conversion apparently occur at different places in the vascular tree and therefore could not be carried out by the same enzyme. Differential inhibition by 2-mercaptoethanol and the bradykinin potentiating peptide, Pyr-Lys-Trp-Ala-Pro, support this postulate. One rat was found which had no pulmonary kininase but could convert angiotensin I to angiotensin II. In addition, infusion of large doses of known inhibitors of lung converting enzyme had no effect on either angiotensin I conversion or bradykinin inactivation in this system. These results support the idea that the pulmonary vasculature is not a major site for conversion of angiotensin I in the rat.
通过在静脉内或动脉内给予这些物质期间监测实验动物的全身血压反应,研究了大鼠肺血管系统在缓激肽、血管紧张素I和5-羟色胺体内代谢中的作用。无论注射途径如何,观察到基本相同的血压反应,这表明血管紧张素I或II以及5-羟色胺都不会被肺血管系统代谢,而缓激肽在通过肺一次时会有95%以上被灭活。在大鼠中,缓激肽失活和血管紧张素转化的主要部分显然发生在血管树的不同部位,因此不可能由同一种酶完成。2-巯基乙醇和缓激肽增强肽Pyr-Lys-Trp-Ala-Pro的差异抑制作用支持了这一假设。发现一只大鼠没有肺激肽酶,但能将血管紧张素I转化为血管紧张素II。此外,在该系统中输注大剂量已知的肺转化酶抑制剂对血管紧张素I转化或缓激肽失活均无影响。这些结果支持了肺血管系统不是大鼠体内血管紧张素I转化的主要部位这一观点。